Effectiveness of Rituximab and Intravenous Immunoglobulin Therapy in Renal Transplant Recipients with Chronic Active Antibody-Mediated Rejection
Author:
Publisher
Elsevier BV
Subject
Transplantation,Surgery
Reference6 articles.
1. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (“CAN”);Solez;Am J Transplant,2007
2. C4d-Positive chronic rejection: a frequent entity with a poor outcome;David-Neto;Transplantation,2007
3. Successful treatment of chronic antibody-mediated rejection with IVIg and rituximab in pediatric renal transplant recipients;Billing;Transplantation,2008
4. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection;Fehr;Transplantation,2009
5. Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation;Levey;Ann Intern Med,1999
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design;Trials;2022-12-22
2. Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin;Stem Cells International;2021-02-10
3. Donor-specific antibodies in kidney transplantation: the University of Wisconsin experience;Current Opinion in Organ Transplantation;2020-10-10
4. Early effects of first‐line treatment with anti‐interleukin‐6 receptor antibody tocilizumab for chronic active antibody‐mediated rejection in kidney transplantation;Clinical Transplantation;2020-06-16
5. Short-Term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection;Kidney360;2020-03-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3